Solid Tumors
AmpliMed presents positive phase I results for Amplimexon in patients with solid tumors
Published in Cancer Weekly, December 12th, 2006
The results were presented by Tomislav Dragovich, MD, PhD, assistant professor of Medicine of the Arizona Cancer Center and lead investigator of the study, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic.
Data from the phase I study show that Amplimexon is well tolerated and provides objective evidence of antitumor activity. The multicenter study involved 49 patients with a variety of solid tumors including melanoma, pancreatic,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-12-12)
More Articles from Cancer Weekly
- Cancer Therapy
Research identifies a human enzyme that could be programmed to kill cancer cells - Drug Development
Clinical data from Adherex's proof-of-mechanism and Phase I eniluracil trials presented - Ankylosing Spondylitis
Data shows Enbrel provides sustained clinical improvements for people with ankylosing spondylitis - Antifungal Agents
Noxafil (posaconazole) Oral Suspension approved in European Union for invasive fungal infections - Breast Cancer
BSD Medical reports greater success in treating breast cancer patients - Business & Finance
Chemokine Therapeutics announces third quarter financial and operating results - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
